Investigational drug · Phase 2
Delamanid
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
44
Any phase or sponsor naming "Delamanid"
First trial start
2022
Jul 26, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Delamanid", any sponsor or status.
Conditions studied
As listed on its trial records.
- Tuberculosis
- Multidrug Resistant Pulmonary Tuberculosis
- Rifampicin-resistant Tuberculosis
Approved drugs for the same conditions: Tuberculosis · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Delamanid" as an intervention, largest first.
- Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis PatientsPivotal-lookingActive, not recruiting
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT03568383 · 5,832 participants · Start Jun 3, 2019 · Primary completion Nov 16, 2026
Drug: Delamanid (DLM); Isoniazid (INH) · For: Tuberculosis, MDR
Sites: Gaborone, Botswana; Rio de Janeiro, Brazil; Port-au-Prince, Haiti · 31 sites in all
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TBPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT06114628 · 2,500 participants (planned) · Start Jan 9, 2024 · Primary completion Feb 24, 2027
Drug: Ganfeborole; BTZ-043 and 11 more · For: Pulmonary Tuberculosis
Sites: Chisinau, Moldova; Cape Town, South Africa; George, South Africa · 11 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00042289 · 1,578 participants · Start Jun 9, 2003 · Primary completion Sep 30, 2020
Drug: atazanavir/cobicistat; darunavir/ritonavir dosage #1 and 55 more · For: HIV Infections
Sites: Birmingham, Alabama; La Jolla, California; Long Beach, California · 62 sites in all
Beijing Children's HospitalAcademic, hospital or other
NCT03625739 · 800 participants (planned) · Start Jul 1, 2018 · Primary completion Oct 1, 2026
Drug: anti-tuberculosis drug · For: Tuberculosis
Sites: Beijing, China
- Evaluating Newly Approved Drugs for Multidrug-resistant TBPivotal-lookingCompleted
Médecins Sans Frontières, FranceAcademic, hospital or other
NCT02754765 · 754 participants · Start Dec 2016 · Primary completion Jun 2023
Drug: Bedaquiline; Delamanid and 6 more · For: Tuberculosis, Multidrug-Resistant; Infection, Bacterial; Pulmonary Tuberculoses
Sites: Tbilisi, Georgia; Pune, India; Almaty, Kazakhstan · 12 sites in all
Beijing Chest HospitalAcademic, hospital or other
NCT04421495 · 608 participants · Start Jul 16, 2020 · Primary completion Jun 16, 2022
Drug: Delamanid · For: Multidrug Resistant Tuberculosis
Sites: Beijing, China; Changsha, China; Chengdu, China · 25 sites in all
- Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant TuberculosisPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01424670 · 511 participants · Start Sep 2, 2011 · Primary completion Jul 4, 2016
Drug: Delamanid + OBR; Placebo + OBR · For: Multidrug-resistant Tuberculosis
Sites: Tartu, Estonia; Riga, Latvia; Šiauliai, Lithuania · 17 sites in all
- A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00685360 · 481 participants · Start May 8, 2008 · Primary completion Jun 11, 2010
Drug: Delamanid; Optimized Background Regimen (OBR) and 1 more · For: Tuberculosis, Pulmonary; Tuberculosis, Multidrug Resistant; Extensively Drug-Resistant Tuberculosis
Sites: San Antonio, Texas; Beijing, China; Shanghai, China · 17 sites in all
Wits Health Consortium (Pty) LtdAcademic, hospital or other
NCT04062201 · 402 participants · Start Aug 22, 2019 · Primary completion Apr 15, 2024
Drug: Bedaquiline Oral Tablet; Linezolid Oral Tablet and 9 more · For: Tuberculosis; Pre-XDR-TB; Extensively Drug-Resistant Tuberculosis and 2 more
Sites: Port Elizabeth, South Africa; Durban, South Africa
- Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)Pivotal-lookingCompleted
Médecins Sans Frontières, FranceAcademic, hospital or other
NCT03896685 · 323 participants · Start Apr 6, 2020 · Primary completion Oct 4, 2024
Drug: Bedaquiline 100 MG; Delamanid 50 MG Oral Tablet and 3 more · For: Tuberculosis, Multidrug-Resistant; Tuberculosis; Pulmonary Tuberculoses and 3 more
Sites: Pune, India; Almaty, Kazakhstan; Maseru, Lesotho · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Neuropsychiatric effects of cycloserine with bedaquiline, delamanid, and conventional therapy in drug-resistant tuberculosis: a multicenter retrospective cohort study from China.
Li Z, Liu Y, Li Z, et al. · Infect Med (Beijing) 2026
- Assessing Multiple Treatment Regimens for Tuberculosis.
Esmail H, Paton NI, Schildkraut JA, et al. · N Engl J Med 2026
- Prevalence of new and repurposed drug resistance and associated genetic variants among rifampicin-resistant Mycobacterium tuberculosis in Shenzhen, China: a population-based study.
Li D, Zhang J, Xu P, et al. · Int J Antimicrob Agents 2026
- Preclinical Study on Novel Treatment Regimen for Elderly Patients with Drug-Sensitive Pulmonary Tuberculosis.
Zhou J, Wang BQ, Zhang YJ, et al. · Int J Mol Sci 2026
- Mechanism of the M. tuberculosis DprE1-DprE2 epimerase complex and inhibition by anti-tubercular drugs.
Gao S, Wu F, Zhang Y, et al. · Nat Chem Biol 2026
- Isolated Forearm Abscess with Bilateral Psoas Abscesses: An Unusual Presentation of Extrapulmonary Preextensively Drug-resistant Tuberculosis without Pulmonary Involvement.
Gabhale S, Goud BVK, Guniganti SK · Ann Afr Med 2026
Also in development for Tuberculosis
- BCGPhase 38 trials
ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis
- MTBVACBBV169Phase 32 trials
Biofabri, S.L · Tuberculosis, Tuberculosis (TB)
- TB-PPDPurified Protein Derivative of TuberculinPhase 32 trials
Chengdu CoenBiotech Co., Ltd · Tuberculosis, Latent Tuberculosis Infection
- BNT164a1Phase 21 trial
BioNTech SE · Tuberculosis
- BNT164b1Phase 21 trial
BioNTech SE · Tuberculosis
- BTZ-043Phase 21 trial
GSK · Tuberculosis
- GSK3036656Phase 21 trial
GSK · Tuberculosis
- JDB0131Phase 21 trial
WestVac Biopharma Co., Ltd. · Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.